brexpiprazole + paroxetine

Brexpiprazole + paroxetine CR is a combination therapy being investigated for the treatment of Post-Traumatic Stress Disorder (PTSD). Brexpiprazole is an atypical antipsychotic that acts as a serotonin-dopamine activity modulator (SDAM), providing partial agonism at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, while acting as an antagonist at 5-HT2A and 5-HT7 receptors. Paroxetine CR is a controlled-release formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine, which increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT). The combination is designed to address the complex symptomatology of PTSD by combining the antidepressant and anxiolytic effects of an SSRI with the mood-stabilizing and receptor-modulating properties of brexpiprazole. This synergistic approach aims to improve symptoms such as intrusive thoughts, avoidance, and hyperarousal more effectively than SSRI monotherapy. The combination is being developed by Otsuka Pharmaceutical and Lundbeck.

Other names

brexpiprazole + paroxetine CRbrexpiprazole plus paroxetine controlled-releaseOPC-34712 + paroxetine CR